Webster Brian Daniel 4

What Happened
Brian Daniel Webster, President and Chief Executive Officer of Kestra Medical Technologies, had 176,470 shares issued to him on July 15, 2026 upon vesting of performance-based RSUs (PSUs) granted July 17, 2025 (acquired at $0.00). On the same date he disposed of 15,000 shares in three open-market/private-sale transactions for aggregate proceeds of approximately $336,610 (11,216 shares at a weighted avg $22.01 ≈ $246,870; 784 shares at $22.63 ≈ $17,745; 3,000 shares at $24.00 ≈ $71,995).

Key Details

• Transaction date: July 15, 2026; Form 4 filed July 17, 2026 (timely).
• Award: 176,470 shares from PSUs (100% vested); acquisition price reported $0.00.
• Sales: 15,000 total shares sold for combined proceeds ≈ $336,610 (see per-lot weighted averages above). Reported sale price ranges: $21.45–$22.44, $22.45–$23.00, and $23.49–$24.10 (weighted averages reported in filing).
• Sales were reported as occurring pursuant to a Rule 10b5-1 trading plan adopted Sept 29, 2025.
• Shares owned after the transactions are not specified in the provided excerpt.
• Transaction codes in filing: A = Award/Acquisition (PSUs); S = Sale.

Context
The 176,470 shares represent performance-based RSUs that vested (compensation), not an open-market purchase. The subsequent sales were executed under a pre-established 10b5-1 plan, which typically indicates pre-arranged transactions rather than opportunistic trading; filings do not state insider motivation. Purchases generally carry stronger positive signaling than routine vesting or pre-planned sales.